Title: Significance of D-dimer in acute ischemic stroke patients with large vessel occlusion accompanied by active cancer

Title: Significance of D-dimer in acute ischemic stroke patients with large vessel occlusion accompanied by active cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Title: Significance of D-dimer in acute ischemic stroke patients with large vessel occlusion accompanied by active cancer Kwang Hyun Pan, Jaeyoun Kim, Jong-Won Chung, Keon Ha Kim, Oh Young Bang, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-512754/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: This study aimed to investigate clinical outcome predictors of acute stroke patients with large vessel occlusion and active cancer and validate the significance of d-dimer levels for endovascular thrombectomy decisions. Methods: We analyzed a prospectively collected hospital-based stroke registry to determine clinical EVT outcomes of acute stroke patients within 24 hours with following criteria: age≥18 years, NIHSS≥6, and internal carotid artery or middle cerebral artery lesion. All patients were classified into EVT and non-EVT groups. Patients were divided into two groups by initial d-dimer level. We explored variables potentially associated with successful recanalization as well as 3-month functional outcomes and mortality rates. Results: Among 68 patients, 36 were treated with EVT, with successful recanalization in 55.6%. The low d-dimer group showed a higher rate of successful recanalization and favorable outcome than the high d-dimer group. The mortality rate was higher in the high d-dimer group. EVT and high d-dimer level were independent predictors of mortality, whereas lesion volume and low d-dimer level were independently associated with favorable outcomes. Conclusions: d-dimer level is a prognostic factor in acute LVO stroke patients with active cancer, and its high value for EVT decisions provisionally supports its testing in this patient population. Neurology cancer-related stroke D-dimer endovascular thrombectomy large vessel occlusion recanalization Figures Figure 1 Figure 2 Figure 3 Introduction Endovascular thrombectomy (EVT) is an established treatment modality for acute stroke patients with large vessel occlusion (LVO). 1 In acute stroke with LVO, current guidelines recommend considering EVT as positively as possible if it meets the criteria. However, there are many unanswered questions regarding the choice of EVT in acute stroke patients with active cancer. There has been a growing number of acute ischemic stroke patients with active cancer due to advances in cancer treatment and the expanding aging population. About 5% of hospitalized ischemic stroke patients have comorbid cancer; among them, 3.1% have LVO treated by EVT. 2 Ischemic stroke associated with active cancer has different behaviors due to the specific etiologic mechanism and outcomes. Stroke patients with active cancer usually have poorer outcomes, have high mortality rates, and are at a higher risk of bleeding complications than non-cancer stroke patients. In the choice of acute or chronic therapy for stroke patients with active cancer, cancer-related coagulopathy and anti-cancer treatments such as chemotherapy and radiotherapy should be considered. 3 In addition, the short life expectancy of advanced cancer patients makes it difficult to choose aggressive therapy, such as intravenous thrombolysis and endovascular intervention, in the setting of an acute stroke. Therefore, the paucity of evidence makes it difficult to determine EVT in acute stroke patients with active cancer. Previous studies stressed the need for cautious patient selection for EVT among those with active cancer because of poor prognosis despite the similar recanalization rate of cancer patients. 4,5 We, thus, aimed to explore the overall clinical outcomes and predictors of LVO in patients with acute stroke and active cancer. In particular, d-dimer level is a well-known prognosticator in stroke patients with active cancer. 6,7 Therefore, this study focused on the clinical implication of baseline d-dimer level on the choice of EVT among acute stroke patients with active cancer. Methods Study design and patient selection This was retrospective analysis of a prospectively collected stroke registry based on a single tertiary hospital that enrolled patients with acute stroke or transient ischemic attack within 7 days from February 2011 to April 2020. The institutional review board of Samsung Medical Center approved the study protocol (2016-08-064). Because anonymized and open data were used in this study, the board waived the requirement for informed consent. All research was conducted in accordance with the principles of the Declaration of Helsinki. In this study, we screened the participants according to the following criteria: age≥18 years; NIHSS score≥6; lesion vessel in the internal carotid artery, middle cerebral artery M1 or M2 segment, time of stroke onset within 24 hours, and presence of active cancer at presentation. Active cancer was defined when they met the following criteria: newly diagnosed cancer in 6 months; treatment with anti-cancer therapy such as surgery, chemotherapy, and radiation therapy in 6 months; recurrent cancer in 6 months; or metastatic cancer in 6 months. Clinical outcome assessment We assessed the successful recanalization rate defined as mTICI grade 2b or 3. 8 Hemorrhagic transformation was assessed on computed tomography or magnetic resonance imaging follow-up after EVT. We assessed the NIHSS score at the initial visit and at discharge to analyze short-term neurologic improvement. Clinical outcome measurements at 3 months included assessments of mortality and disability according to the modified Rankin Scale (mRS) score. We defined an mRS score of 0–2 as a favorable clinical outcome and an mRS score of 3–6 as a poor clinical outcome. The cause of death was stroke-related deaths and other medical problem–related deaths. Marked neurological improvement was defined as a decrease of 10 points or more in the NIHSS score during the hospital stay or a fully improved neurological deficit. Imaging and laboratory data The infarcted lesion volume (milliliters) was analyzed using a validated lesion volume analysis in-house software. Laboratory data, such as complete blood counts, d-dimer level, lipid panel, and C-reactive protein level, were obtained from the first blood sample collected at the emergency department. Statistical analysis Because the primary purpose of this study was to describe the outcomes of acute stroke with LVO and active cancer associated with EVT, patients were classified into EVT and non-EVT groups. We also divided the patients into two groups based on their initial d-dimer levels. The optimal d-dimer cut-off point predicting a 3-month favorable outcome was determined using Youden’s J statistics. (sensitivity+specificity:1). Because the optimal cut-off point predicting a 3-month favorable outcome was 3.825 μg/mL, we simply divided the patients into a low initial d-dimer level group (n=25; d-dimer level4). Intergroup comparisons were performed using the Wilcoxon rank-sum test for continuous variables and the χ 2 test for categorical variables. Univariate and multivariate logistic regression analyses were performed to identify factors associated with poor clinical outcomes. The stepwise forward selection method was used to select variables for the multivariate analysis. The p value threshold for entry was set to 0.05. Propensity score matching was conducted to adjust for age, sex, hypertension, diabetes mellitus, dyslipidemia, and atrial fibrillation between patients treated with EVT and those treated with low and high d-dimer levels. All statistical analyses were performed using SPSS statistics 25.0, and values of p<0.05 were considered statistically significant. Results Baseline characteristics During the study period, a total of 5537 patients were enrolled in the SMC stroke registry (Fig. 1 ). Among them, 243 patients met the criteria for acute stroke with LVO and 81 patients with active cancer were selected. Finally, we analyzed the data of 68 patients after the exclusion of an additional 13 patients due to no 3-month outcome (n = 6), posterior circulation involvement only (n = 3), missing laboratory test (n = 2), EVT performed at another hospital (n = 2), and posterior circulation stroke (n = 11). The mean patient age was 65.59 years, 36 (52.9%) were male, 32 (47%) had lung cancer, 36 (52.9%) had distant metastasis, and the average initial NIHSS score was 14.17. 36 patients (52.9%) were treated with EVT, while 32 patients (47.1%) were treated medically. The mean initial d -dimer level was 16.07 µg/mL. The baseline characteristics of each group are presented in Table 1 . The EVT group had more hypertension and atrial fibrillation, a higher mean platelet count, lower mean low-density lipoprotein (LDL) cholesterol, and lower d -dimer levels than the non-EVT group. The lesion volume was smaller and the onset-to-emergency room time was shorter than that in the non-EVT group. Age, sex, baseline NIHSS score, other comorbid disease, laboratory results, and occluded vessel site did not differ significantly between groups. Table 1 Patients’ baseline characteristics Non-EVT (n = 32) EVT (n = 36) P value d -dimer level 4 (n = 43) P value Age, years 63.4 ± 8.5 67.6 ± 10.4 0.08 70.6 ± 10.3 62.67 ± 8.2 0.20 Male sex 16 (50) 20 (55.6) 0.65 12 (48.0) 24 (55.8) 0.53 Baseline NIHSS score 14.4 ± 6.4 14.5 ± 6.2 0.94 14.3 ± 5.8 14.6 ± 6.6 0.88 Hypertension 7 (21.9) 18 (50.0) 0.02 12 (48.0) 13 (30.2) 0.14 Diabetes 5 (15.6) 4 (11.1) 0.58 4 (16.0) 5 (11.6) 0.61 Hyperlipidemia 3 (9.4) 9 (25.0) 0.09 6 (24.0) 6 (14.0) 0.30 Atrial fibrillation 0 (0) 11 (30.6) < 0.01 8 (32.0) 3 (7.0) < 0.01 Previous history of stroke 5 (15.6) 6 (16.7) 0.91 4 (16.0) 7 (16.3) 0.98 Smoking 8 (25.0) 15 (41.7) 0.15 9 (36.0) 14 (32.6) 0.77 Alcohol 3 (9.4) 7 (19.4) 0.24 2 (8.0) 8 (18.6) 0.23 Lung cancer 14 (43.8) 18 (50.0) 0.61 13 (52.0) 19 (44.2) 0.53 Distant metastasis 18 (56.3) 18 (50.0) 0.61 9 (36.0) 27 (62.8) 0.03 Hemoglobin (g/dL) 10.8 ± 2.2 11.4 ± 2.2 0.21 11.95 ± 1.88 10.6 ± 2.3 0.02 Platelets (10 3 /mm 3 ) 164.8 ± 125.3 183.2 ± 73.4 0.04 229.48 ± 93.04 142.5 ± 91.8 < 0.01 INR 1.3 ± 0.3 1.1 ± 0.2 < 0.01 1.05 ± 0.10 1.3 ± 0.3 < 0.01 d -dimer 21.4 ± 18.8 11.3 ± 15.8 0.02 - - LDL cholesterol (mg/dL) 96.5 ± 33.4 81.0 ± 27.8 0.03 90.04 ± 27.33 87.3 ± 33.7 0.34 C-reactive protein (mg/dL) 5.4 ± 5.2 7.1 ± 10.9 0.26 3.73 ± 5.72 7.8 ± 9.7 < 0.01 Occlusion site ICA 5 (15.6) 13 (36.1) 0.06 7 (28.00) 11 (25.6) 0.83 M1 12 (37.5) 15 (41.7) 0.73 10 (40.00) 17 (39.5) 0.97 M2 15 (46.9) 8 (22.2) 0.03 8 (32.00) 15 (34.9) 0.81 Lesion volume (mL) 71.4 ± 63.7 26.0 ± 33.9 < 0.01 20.21 ± 22.49 63.1 ± 61.6 < 0.01 Onset-to-ER (min) 135 (79–385) 60 (25–113) < 0.01 56 (27–95) 120 (60–335) 0.01 Door-to-puncture (min) - 119 (97–143) - 106 (93–122) 134 (100–195) 0.19 Values are presented as n (%), mean ± standard deviation, or median (interquartile range). EVT, endovascular therapy; INR, international normalized ratio; LDL, low-density lipoprotein; NIHSS, National Institute of Health Stroke Scale The high d -dimer group had more atrial fibrillation, more distant metastasis, lower mean hemoglobin level, lower mean platelet count, prolonged prothrombin time, and higher mean C-reactive protein levels than the low d -dimer group. The lesion volume was significantly larger and the onset-to-emergency room time was longer than that in the low d -dimer group. Age, sex, baseline NIHSS, other comorbid disease, laboratory results, and occluded vessel site did not differ significantly between the groups. Clinical outcomes The clinical outcomes of each group are presented in Table 2 . Among the 36 patients treated with EVT, 20 (55.6%) had successful recanalization. The low d -dimer group showed a higher successful recanalization rate than the high d -dimer group (73.68% vs. 35.29%, p = 0.02) The incidence of hemorrhagic transformation was not significantly different. The EVT group showed a lower mean NIHSS score at discharge than the non-EVT group (median, 5.5 [interquartile range (IQR), 1.75–14] vs. 16 [IQR, 7–42], p < 0.01), and the high d -dimer group showed a higher mean NIHSS score at discharge than the low d -dimer group (median, 15.7 [IQR, 6.5–40] vs. 4 [IQR, 1–13], p < 0.001). Table 2 Clinical outcomes by EVT and d -dimer groups Non-EVT (n = 32) EVT (n = 36) P value d -dimer level 4 (n = 43) P-value Successful recanalization (mTICI 2b–3) - 20 (55.6) - 14 (73.7) 6 (35.3) 0.02 Hemorrhagic transformations 5 (15.6) 6 (16.7) 0.91 4 (16.0) 7 (16.3) 0.98 NIHSS at discharge 16 (7–42) 5.5 (1.5–14) < 0.01 4 (1– 13) 6 (15.7–42) < 0.01 Median mRS score at 3 months 6 (4.75–6) 3.5 (1–6) < 0.01 1 (1–3) 6 (5–6) < 0.01 Favorable outcomes (mRS score of 0–2) 5 (15.6) 13 (36.1) 0.06 15 (60.0) 3 (7.0) < 0.01 Mortality at 3 months 22 (68.8) 12 (33.3) < 0.01 3 (12.0) 31 (72.1) < 0.01 Values are number (%) or median (interquartile range). The median 3-month mRS score was significantly better in the EVT group than in the non-EVT group (median, 3.5 [IQR, 1–6] vs. 6 [IQR, 4.75–6], p = 0.01) and significantly better in the low d -dimer group than in the high d -dimer group (median, 1 [IQR, 1–3] vs. 6 [IQR, 5–6], p < 0.01). The EVT group had more favorable outcomes, but the difference was not statistically significant. The low d -dimer group had significantly more favorable outcomes than the high d -dimer group. The 3-month mortality rate was significantly higher in the non-EVT group than the EVT group and the high d -dimer group than the low d- dimer group (p < 0.01) (68.75% vs. 33.33%, 58.85% vs. 10.53%, respectively). EVT and non-EVT groups showed poor 3-month mRS scores with high d -dimer levels. Patients with low d -dimer levels and EVT showed the best outcomes, while those with high d -dimer levels and non-EVT showed the worst outcomes. (Fig. 2 ) The cause of death was stroke-related in six patients (17.6%) and other medical problem–related deaths in 28 patients (82.4%). A total of 10 (27.8%) patients showed early dramatic neurologic improvement in the EVT group. Among them, 10 underwent EVT and reported early dramatic improvement, 3 (30%) died, and the other 7 (70%) were alive at 3 months. The seven survivors included six from the low d -dimer group and one from the high d -dimer group. Receiver operating characteristic curve analysis Figure 3 shows the ROC of favorable outcomes and mortality by initial d -dimer level. The areas under the curve were 0.896 and 0.869, respectively. The initial d -dimer level was significantly related to a 3-month favorable outcome and mortality. Logistic regression analysis Univariate and multivariate logistic regression analyses are presented in Table 3 . The risk factors for 3-month mortality were EVT (OR, 0.297; p = 0.027) and an initially high d -dimer level (OR, 16.230; p < 0.001). The negative correlation factors of clinically favorable outcomes were lesion volume (OR, 0.936; p = 0.009) and high d -dimer levels (OR, 0.098; p = 0.005). Table 3 Regression analysis of mortality and favorable outcomes Mortality Favorable outcome Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value Age 0.96 (0.91–1.01) 0.12 1.03 (0.97–1.09) 0.37 Male sex 1.61 (0.62–4.19) 0.33 0.63 (0.21–1.86) 0.40 Baseline NIHSS 1.05 (0.97–1.13) 0.25 0.94 (0.86–1.02) 0.14 Hypertension 0.88 (0.33–2.36) 0.80 0.58 (0.18–1.87) 0.36 Diabetes 1.29 (0.32–5.30) 0.72 1.47 (0.33–6.60) 0.62 Hyperlipidemia 0.43 (0.12–1.61) 0.21 2.36 (0.64–8.71) 0.20 Atrial fibrillation 0.51 (0.14–1.95) 0.33 1.05 (0.25–4.49) 0.95 Smoking 0.88 (0.32–2.40) 0.80 0.68 (0.21–2.23) 0.53 Alcohol 0.62 (0.16–2.44) 0.50 0.27 (0.03–2.28) 0.23 Lung cancer 0.79 (0.30–2.05) 0.63 3.00 (0.97–9.30) 0.06 Distant metastasis 2.05 (0.78–5.39) 0.15 1.15 (0.39–3.41) 0.80 Hemoglobin 0.76 (0.60–0.97) 0.03 0.78 (0.60–1.01) 0.06 1.12 (0.88–1.43) 0.38 Platelet count 0.99 (0.99–1.00) 0.03 1.00 (0.99–1.00) 0.20 1.01 (1.00–1.02) 0.01 1.01 (1.00–1.02) 0.03 LDL-cholesterol 1.00 (0.98–1.01) 0.68 1.01 (0.99–1.02) 0.51 C-reactive protein 1.08 (1.00–1.17) 0.07 0.93 (0.83–1.03) 0.15 Occluded segment MCA M1 1.45 (0.55–3.84) 0.46 0.49 (0.15–1.58) 0.23 MCA M2 0.67 (0.25–1.85) 0.44 1.87 (0.62–5.66) 0.27 Distal ICA 1.00 (0.34–2.94) 1.00 1.10 (0.33–3.67) 0.88 Lesion volume, mL 1.01 (1.00–1.02) 0.10 0.93 (0.88– 0.98) < 0.01 0.94 (0.89– 0.98) < 0.01 Onset-to-ER 1.00 (1.00–1.01) 0.03 1.00 (1.00–1.01) 0.05 0.10 (0.99–1.00) 0.11 Mechanical thrombectomy 0.23 (0.08–0.63) 4 18.94 (4.78–75.16) < 0.01 16.23 (4.02–65.58) < 0.01 0.05 (0.01–0.21) < 0.01 0.10 (0.02–0.50) 0.05 Discussion A significant proportion of acute stroke patients with LVO had active cancer at presentation, a low successful recanalization rate, a higher probability of disability at 3 months, and higher mortality. d -dimer level was an independent prognostic factor for favorable outcomes and mortality among acute stroke patients with active cancer irrespective of EVT. In addition, the initial d -dimer level tended to be inversely correlated with recanalization grade, although the trend was not statistically significant. Therefore, the treatment effect of EVT was affected by the baseline d -dimer level, suggesting that d -dimer can be a useful determinant of EVT in acute stroke patients with active cancer. Previous studies showed a significantly worse prognosis in patients with active cancer than in those without cancer when treated with EVT. 4 , 5 These results suggest that conventional criteria for the decision of EVT were inappropriate for acute stroke patients with active cancer, suggesting the unmet need for new prognostic factors. The etiology of stroke due to cancer-related coagulopathy is thought to differ from that of conventional stroke mechanisms. There have been emerging ideas of cancer-related stroke mechanisms, including intravascular coagulopathy, paradoxical embolisms with venous thromboembolism, and nonbacterial thrombotic endocarditis. 9 Regarding these distinguishing etiologies of cancer-associated stroke, special consideration was made of unique stroke patterns involving multiple scattered lesions in multiple vascular territories that were associated with elevated d -dimer levels. 10 d -dimer, a fibrin degradation product of a blood clot, is known to reflect coagulation mechanisms and hypercoagulability by direct measurement of activated coagulation and fibrinolysis. 11 Several previous studies suggested the prognostic and diagnostic value of elevated d -dimer levels as a risk factor for stroke in patients with cancer or cardiovascular diseases. 6 , 7 Cancer patients with high d -dimer levels tend to show poor outcomes and a high mortality rate. 12 Elevated d -dimer levels show the distinctive etiology of stroke but also reflect the general medical condition of patients with underlying cancer. 7 Therefore, we hypothesized that the baseline d -dimer level in acute stroke patients with active cancer can be used to predict the overall outcome. Although the d -dimer level is used as a unique thrombosis biomarker, a specific level that predicts ischemic stroke is unknown. After the adjustment for EVT, our study showed that patients with elevated d -dimer levels above 4 µg/mL had about a 16-fold higher risk of death and a 90% lower chance of a favorable outcome at 90 days. We assumed that the d -dimer level might help guide whether to proceed with EVT and predict clinical outcomes in LVO cancer stroke patients. However, considering the cause of mortality among our research results, the general medical condition is more important for prognosis than the stroke itself. In determining the EVT of cancer patients, in addition to the pre-existing criteria, general medical conditions such as d -dimer should be considered together. Approximately one-third of EVT cancer patients showed dramatic rapid neurological improvement, and the majority of had low initial d -dimer levels and mortality was numerically higher in the high d -dimer group (two-thirds of patients) despite the achievement of the early dramatic neurological improvement. Therefore, we should assess the initial d -dimer level when choosing EVT for a cancer patient, and if the d -dimer level is low, EVT can be considered appropriate. Baseline d -dimer levels were associated with recanalization grade. The unique pathophysiology of intravascular coagulopathy, which often occurs in cancer patients, increases d -dimer levels. 6 Tissue factors, inflammatory cytokines, or cancer procoagulants from cancer cells affect factor X activation in the coagulation cascade. 10 This mechanism results in the formation of a solid fibrin clot within the vessel without any embolic thrombus. A previous study revealed that thrombi from EVT in cancer patients showed a significantly higher fraction of platelets and fibrin-rich components than those in non-cancer stroke patients. 13 , 14 . Further studies are needed to reveal the specific mechanism in cancer stroke patients. This study had several limitations. First, this study was conducted in a single center and included a relatively small sample size. Second, different cancer types and stages may have different effects on stroke. Third, the etiologies of stroke in patients with cancer may be diverse. In particular, atrial fibrillation was significantly more frequently observed in the EVT group. Despite these limitations, our study revealed a significant relationship between initial d -dimer levels and clinical outcomes in patients with cancer-associated stroke and LVO. Conclusion In conclusion, active cancer patients with LVO stroke treated with EVT showed low recanalization and poor clinical outcomes correlated with d -dimer levels. The initial d -dimer level was an independent factor predicting favorable clinical outcomes and mortality in patients with active cancer patients with LVO stroke. Therefore, careful patient selection for EVT among cancer-associated stroke patients with LVO according to the initial d -dimer level is warranted. Acronyms EVT endovascular thrombectomy LVO large vessel occlusion mTICI modified Treatment in Cerebral Infarction mRS modified Rankin Scale NIHSS National Institutes of Health Stroke Scale Declarations Data availability : All of the data supporting the conclusions of this article are included within the article. The authors declare that data will be made available upon request. Acknowledgments : None Competing interests : The authors declare no competing interests. Sources of funding : This study was funded by national research project ID 2020M3E5D2A01084891 from ministry of Health and Welfare in Republic of Korea. Author contributions: K.H.P peformed statistical analysis and wrote draft of manuscript, W.K.S made critical revisions of manuscript, tables and figures, and the other authors collected and stratified patient data. All authors contributed to and approved the final manuscript. References 1 Jovin, T. G. et al. Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. New England Journal of Medicine 372 , 2296-2306, doi:10.1056/NEJMoa1503780 (2015). 2 Rinaldo, L., Cloft, H. J., Rangel Castilla, L., Rabinstein, A. A. & Brinjikji, W. Utilization rates of tissue plasminogen activator and mechanical thrombectomy in patients with acute stroke and underlying malignancy. J Neurointerv Surg 11 , 768-771, doi:10.1136/neurintsurg-2018-014480 (2019). 3 Navi, B. B. & Iadecola, C. Ischemic stroke in cancer patients: A review of an underappreciated pathology. Ann Neurol 83 , 873-883, doi:10.1002/ana.25227 (2018). 4 Lee, D. et al. Intra-arterial thrombectomy for acute ischaemic stroke patients with active cancer. J Neurol 266 , 2286-2293, doi:10.1007/s00415-019-09416-8 (2019). 5 Jung, S. et al. Procedural and clinical outcomes of endovascular recanalization therapy in patients with cancer-related stroke. Interv Neuroradiol 24 , 520-528, doi:10.1177/1591019918776207 (2018). 6 Ryu, J. A., Bang, O. Y. & Lee, G. H. D-dimer levels and cerebral infarction in critically ill cancer patients. BMC Cancer 17 , 591, doi:10.1186/s12885-017-3588-7 (2017). 7 Haapaniemi, E. & Tatlisumak, T. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol Scand 119 , 141-150, doi:10.1111/j.1600-0404.2008.01081.x (2009). 8 Zaidat, O. O. et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 44 , 2650-2663, doi:10.1161/STROKEAHA.113.001972 (2013). 9 Schwarzbach, C. J. et al. Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke 43 , 3029-3034, doi:10.1161/STROKEAHA.112.658625 (2012). 10 Bang, O. Y. et al. Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. J Stroke 22 , 1-10, doi:10.5853/jos.2019.02278 (2020). 11 Tripodi, A. D-dimer testing in laboratory practice. Clin Chem 57 , 1256-1262, doi:10.1373/clinchem.2011.166249 (2011). 12 Hou, H. et al. Association of Level and Increase in D-Dimer With All-Cause Death and Poor Functional Outcome After Ischemic Stroke or Transient Ischemic Attack. J Am Heart Assoc 10 , e018600, doi:10.1161/jaha.120.018600 (2021). 13 Park, H. et al. Histological features of intracranial thrombi in stroke patients with cancer. Ann Neurol 86 , 143-149, doi:10.1002/ana.25495 (2019). 14 Fu, C. H. et al. Fibrin and Platelet-Rich Composition in Retrieved Thrombi Hallmarks Stroke With Active Cancer. Stroke 51 , 3723-3727, doi:10.1161/strokeaha.120.032069 (2020). Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-512754","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":26355087,"identity":"8e17829b-2945-48d5-91a5-c7ed4208fcdd","order_by":0,"name":"Kwang Hyun Pan","email":"","orcid":"","institution":"Samsung Medical Center, Sunkyunkwan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Kwang","middleName":"Hyun","lastName":"Pan","suffix":""},{"id":26355088,"identity":"7554b38f-3a37-45a1-9a64-df062a632efb","order_by":1,"name":"Jaeyoun Kim","email":"","orcid":"","institution":"Samsung Medical Center, Sunkyunkwan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jaeyoun","middleName":"","lastName":"Kim","suffix":""},{"id":26355089,"identity":"90840281-68c6-4531-a778-cf839a900dca","order_by":2,"name":"Jong-Won Chung","email":"","orcid":"","institution":"Samsung Medical Center, Sunkyunkwan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jong-Won","middleName":"","lastName":"Chung","suffix":""},{"id":26355090,"identity":"b2dcc348-9894-4cc2-af55-58b80240c9f4","order_by":3,"name":"Keon Ha Kim","email":"","orcid":"","institution":"Samsung Medical Center, Sunkyunkwan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Keon","middleName":"Ha","lastName":"Kim","suffix":""},{"id":26355091,"identity":"e30bc3ff-1f8d-4204-ad22-1450de7a106f","order_by":4,"name":"Oh Young Bang","email":"","orcid":"","institution":"Samsung Medical Center, Sunkyunkwan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Oh","middleName":"Young","lastName":"Bang","suffix":""},{"id":26355092,"identity":"049c12d8-783c-49dc-bd6a-a07846ebfd58","order_by":5,"name":"Pyoung Jeon","email":"","orcid":"","institution":"Samsung Medical Center, Sunkyunkwan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Pyoung","middleName":"","lastName":"Jeon","suffix":""},{"id":26355093,"identity":"191854c6-3dee-445c-8018-2cdb33650f02","order_by":6,"name":"Gyeong-Moon Kim","email":"","orcid":"","institution":"Samsung Medical Center, Sunkyunkwan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Gyeong-Moon","middleName":"","lastName":"Kim","suffix":""},{"id":26355094,"identity":"efba88cf-9dc6-4f2f-a8ef-2e1c846fdfd9","order_by":7,"name":"Woo-Keun Seo","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4klEQVRIiWNgGAWjYFADZgbGB0CKh48o1QcgWpgNQFrYiNfCwMAmASYJqdZtP/z484eKO3Ly7ezPKr/m2MmwMTA/fHQDjxazM2lmEgfOPDM2OMxjdlt2WzLQYWzGxjn4tNxgMGM42HY4cQMzD9ttyW1AEugdafxa2D9/OPjvcOL8ZvZnxZLb6onRwmMgcbDhcGLDYQYzxo/bDhOh5UxOmcSZY4dBfjGWZtx2nIeNmZBfjh/f/KGi5rCcfP/xhx9/bqu252dvfvgYnxYUwMwDJolVDgKMP0hRPQpGwSgYBSMGAABGI0gE9ZMH0AAAAABJRU5ErkJggg==","orcid":"","institution":"Samsung Medical Center, Sunkyunkwan University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Woo-Keun","middleName":"","lastName":"Seo","suffix":""}],"badges":[],"createdAt":"2021-05-10 11:14:03","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-512754/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-512754/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":9118515,"identity":"a1ad25a0-486f-4fb0-ab42-d2d18967cfac","added_by":"auto","created_at":"2021-05-13 00:31:12","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":887696,"visible":true,"origin":"","legend":"Flow of patient inclusion ","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-512754/v1/5da665a50a11784e2f6b0bc7.jpg"},{"id":9118493,"identity":"abd0da22-eee1-42d6-95af-05f3f3745c2b","added_by":"auto","created_at":"2021-05-13 00:31:10","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":492483,"visible":true,"origin":"","legend":"Distribution of modified 3-month Rankin Scale score by EVT and D-dimer group","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-512754/v1/20c091b12b09965c6c270ab0.jpg"},{"id":9118494,"identity":"5c79e5fa-c800-4dae-810a-e86ee5b89204","added_by":"auto","created_at":"2021-05-13 00:31:10","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":652060,"visible":true,"origin":"","legend":"Receiver operating characteristic curve of D-dimer for the prediction of patient clinical outcomes ","description":"","filename":"3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-512754/v1/c05688aaeb131ac9805dfa0e.jpg"},{"id":13692530,"identity":"d3713e09-9316-4a7a-bf38-1771ce915a69","added_by":"auto","created_at":"2021-09-17 12:43:55","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":601516,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-512754/v1/25225380-05f7-4745-af2d-8d24c64254f3.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Title: Significance of D-dimer in acute ischemic stroke patients with large vessel occlusion accompanied by active cancer","fulltext":[{"header":"Introduction","content":"\u003cp\u003eEndovascular thrombectomy (EVT) is an established treatment modality for acute stroke patients with large vessel occlusion (LVO).\u003csup\u003e1\u003c/sup\u003e In acute stroke with LVO, current guidelines recommend considering EVT as positively as possible if it meets the criteria. However, there are many unanswered questions regarding the choice of EVT in acute stroke patients with active cancer.\u003c/p\u003e\n\u003cp\u003eThere has been a growing number of acute ischemic stroke patients with active cancer due to advances in cancer treatment and the expanding aging population. About 5% of hospitalized ischemic stroke patients have comorbid cancer; among them, 3.1% have LVO treated by EVT.\u003csup\u003e2\u003c/sup\u003e Ischemic stroke associated with active cancer has different behaviors due to the specific etiologic mechanism and outcomes. Stroke patients with active cancer usually have poorer outcomes, have high mortality rates, and are at a higher risk of bleeding complications than non-cancer stroke patients. In the choice of acute or chronic therapy for stroke patients with active cancer, cancer-related coagulopathy and anti-cancer treatments such as chemotherapy and radiotherapy should be considered.\u003csup\u003e3\u003c/sup\u003e In addition, the short life expectancy of advanced cancer patients makes it difficult to choose aggressive therapy, such as intravenous thrombolysis and endovascular intervention, in the setting of an acute stroke. Therefore, the paucity of evidence makes it difficult to determine EVT in acute stroke patients with active cancer. Previous studies stressed the need for cautious patient selection for EVT among those with active cancer because of poor prognosis despite the similar recanalization rate of cancer patients.\u003csup\u003e4,5\u003c/sup\u003e\u003c/p\u003e\n\u003cp\u003eWe, thus, aimed to explore the overall clinical outcomes and predictors of LVO in patients with acute stroke and active cancer. In particular, d-dimer level is a well-known prognosticator in stroke patients with active cancer. \u003csup\u003e6,7\u003c/sup\u003e Therefore, this study focused on the clinical implication of baseline d-dimer level on the choice of EVT among acute stroke patients with active cancer.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cstrong\u003e\u003cem\u003eStudy design and patient selection\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis was retrospective analysis of a prospectively collected stroke registry based on a single tertiary hospital that enrolled patients with acute stroke or transient ischemic attack within 7 days from February 2011 to April 2020. The institutional review board of Samsung Medical Center approved the study protocol (2016-08-064). Because anonymized and open data were used in this study, the board waived the requirement for informed consent. All research was conducted in accordance with the principles of the Declaration of Helsinki. In this study, we screened the participants according to the following criteria: age\u0026ge;18 years; NIHSS score\u0026ge;6; lesion vessel in the internal carotid artery, middle cerebral artery M1 or M2 segment, time of stroke onset within 24 hours, and presence of active cancer at presentation. Active cancer was defined when they met the following criteria: newly diagnosed cancer in 6 months; treatment with anti-cancer therapy such as surgery, chemotherapy, and radiation therapy in 6 months; recurrent cancer in 6 months; or metastatic cancer in 6 months.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eClinical outcome assessment\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe assessed the successful recanalization rate defined as mTICI grade 2b or 3.\u003csup\u003e8\u003c/sup\u003e Hemorrhagic transformation was assessed on computed tomography or magnetic resonance imaging follow-up after EVT. We assessed the NIHSS score at the initial visit and at discharge to analyze short-term neurologic improvement. Clinical outcome measurements at 3 months included assessments of mortality and disability according to the modified Rankin Scale (mRS) score. We defined an mRS score of 0\u0026ndash;2 as a favorable clinical outcome and an mRS score of 3\u0026ndash;6 as a poor clinical outcome. The cause of death was stroke-related deaths and other medical problem\u0026ndash;related deaths. Marked neurological improvement was defined as a decrease of 10 points or more in the NIHSS score during the hospital stay or a fully improved neurological deficit.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eImaging and laboratory data\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe infarcted lesion volume (milliliters) was analyzed using a validated lesion volume analysis in-house software. Laboratory data, such as complete blood counts, d-dimer level, lipid panel, and C-reactive protein level, were obtained from the first blood sample collected at the emergency department.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eStatistical analysis\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBecause the primary purpose of this study was to describe the outcomes of acute stroke with LVO and active cancer associated with EVT, patients were classified into EVT and non-EVT groups. We also divided the patients into two groups based on their initial d-dimer levels. The optimal d-dimer cut-off point predicting a 3-month favorable outcome was determined using Youden\u0026rsquo;s J statistics. (sensitivity+specificity:1). Because the optimal cut-off point predicting a 3-month favorable outcome was 3.825 \u0026mu;g/mL, we simply divided the patients into a low initial d-dimer level group (n=25; d-dimer level\u0026lt;4) and a high d-dimer level group (d-dimer level\u0026gt;4). Intergroup comparisons were performed using the Wilcoxon rank-sum test for continuous variables and the \u0026chi;\u003csup\u003e2\u003c/sup\u003e test for categorical variables. Univariate and multivariate logistic regression analyses were performed to identify factors associated with poor clinical outcomes. The stepwise forward selection method was used to select variables for the multivariate analysis. The p value threshold for entry was set to 0.05. Propensity score matching was conducted to adjust for age, sex, hypertension, diabetes mellitus, dyslipidemia, and atrial fibrillation between patients treated with EVT and those treated with low and high d-dimer levels. All statistical analyses were performed using SPSS statistics 25.0, and values of p\u0026lt;0.05 were considered statistically significant.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eBaseline characteristics\u003c/strong\u003e\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eDuring the study period, a total of 5537 patients were enrolled in the SMC stroke registry (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). Among them, 243 patients met the criteria for acute stroke with LVO and 81 patients with active cancer were selected. Finally, we analyzed the data of 68 patients after the exclusion of an additional 13 patients due to no 3-month outcome (n\u0026thinsp;=\u0026thinsp;6), posterior circulation involvement only (n\u0026thinsp;=\u0026thinsp;3), missing laboratory test (n\u0026thinsp;=\u0026thinsp;2), EVT performed at another hospital (n\u0026thinsp;=\u0026thinsp;2), and posterior circulation stroke (n\u0026thinsp;=\u0026thinsp;11).\u003c/p\u003e\n\u003cp\u003eThe mean patient age was 65.59 years, 36 (52.9%) were male, 32 (47%) had lung cancer, 36 (52.9%) had distant metastasis, and the average initial NIHSS score was 14.17. 36 patients (52.9%) were treated with EVT, while 32 patients (47.1%) were treated medically. The mean initial \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level was 16.07 \u0026micro;g/mL.\u003c/p\u003e\n\u003cp\u003eThe baseline characteristics of each group are presented in Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e. The EVT group had more hypertension and atrial fibrillation, a higher mean platelet count, lower mean low-density lipoprotein (LDL) cholesterol, and lower \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels than the non-EVT group. The lesion volume was smaller and the onset-to-emergency room time was shorter than that in the non-EVT group. Age, sex, baseline NIHSS score, other comorbid disease, laboratory results, and occluded vessel site did not differ significantly between groups.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab1\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003ePatients\u0026rsquo; baseline characteristics\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eNon-EVT\u003c/p\u003e\n\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;32)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eEVT\u003c/p\u003e\n\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;36)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP value\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level\u0026thinsp;\u0026lt;\u0026thinsp;4\u003c/p\u003e\n\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;25)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level\u0026thinsp;\u0026gt;\u0026thinsp;4\u003c/p\u003e\n\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;43)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP value\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAge, years\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e63.4\u0026thinsp;\u0026plusmn;\u0026thinsp;8.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e67.6\u0026thinsp;\u0026plusmn;\u0026thinsp;10.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.08\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e70.6\u0026thinsp;\u0026plusmn;\u0026thinsp;10.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e62.67\u0026thinsp;\u0026plusmn;\u0026thinsp;8.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.20\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMale sex\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e16 (50)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e20 (55.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.65\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e12 (48.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e24 (55.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.53\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eBaseline NIHSS score\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14.4\u0026thinsp;\u0026plusmn;\u0026thinsp;6.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14.5\u0026thinsp;\u0026plusmn;\u0026thinsp;6.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.94\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14.3\u0026thinsp;\u0026plusmn;\u0026thinsp;5.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14.6\u0026thinsp;\u0026plusmn;\u0026thinsp;6.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.88\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHypertension\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7 (21.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18 (50.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.02\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e12 (48.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e13 (30.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.14\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDiabetes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5 (15.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4 (11.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.58\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4 (16.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5 (11.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.61\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHyperlipidemia\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3 (9.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e9 (25.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.09\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (24.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (14.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.30\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAtrial fibrillation\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0 (0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e11 (30.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e8 (32.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3 (7.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePrevious history of stroke\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5 (15.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (16.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.91\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4 (16.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7 (16.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.98\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSmoking\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e8 (25.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15 (41.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e9 (36.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14 (32.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.77\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAlcohol\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3 (9.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7 (19.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.24\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2 (8.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e8 (18.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.23\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLung cancer\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14 (43.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18 (50.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.61\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e13 (52.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e19 (44.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.53\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDistant metastasis\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18 (56.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18 (50.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.61\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e9 (36.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e27 (62.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.03\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHemoglobin (g/dL)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10.8\u0026thinsp;\u0026plusmn;\u0026thinsp;2.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e11.4\u0026thinsp;\u0026plusmn;\u0026thinsp;2.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.21\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e11.95\u0026thinsp;\u0026plusmn;\u0026thinsp;1.88\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10.6\u0026thinsp;\u0026plusmn;\u0026thinsp;2.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.02\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePlatelets (10\u003csup\u003e3\u003c/sup\u003e/mm\u003csup\u003e3\u003c/sup\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e164.8\u0026thinsp;\u0026plusmn;\u0026thinsp;125.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e183.2\u0026thinsp;\u0026plusmn;\u0026thinsp;73.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.04\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e229.48\u0026thinsp;\u0026plusmn;\u0026thinsp;93.04\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e142.5\u0026thinsp;\u0026plusmn;\u0026thinsp;91.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eINR\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.3\u0026thinsp;\u0026plusmn;\u0026thinsp;0.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.1\u0026thinsp;\u0026plusmn;\u0026thinsp;0.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.05\u0026thinsp;\u0026plusmn;\u0026thinsp;0.10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.3\u0026thinsp;\u0026plusmn;\u0026thinsp;0.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e21.4\u0026thinsp;\u0026plusmn;\u0026thinsp;18.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e11.3\u0026thinsp;\u0026plusmn;\u0026thinsp;15.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.02\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLDL cholesterol (mg/dL)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e96.5\u0026thinsp;\u0026plusmn;\u0026thinsp;33.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e81.0\u0026thinsp;\u0026plusmn;\u0026thinsp;27.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e90.04\u0026thinsp;\u0026plusmn;\u0026thinsp;27.33\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e87.3\u0026thinsp;\u0026plusmn;\u0026thinsp;33.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.34\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eC-reactive protein (mg/dL)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5.4\u0026thinsp;\u0026plusmn;\u0026thinsp;5.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7.1\u0026thinsp;\u0026plusmn;\u0026thinsp;10.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.26\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.73\u0026thinsp;\u0026plusmn;\u0026thinsp;5.72\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7.8\u0026thinsp;\u0026plusmn;\u0026thinsp;9.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eOcclusion site\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eICA\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5 (15.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e13 (36.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.06\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7 (28.00)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e11 (25.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.83\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eM1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e12 (37.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15 (41.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.73\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10 (40.00)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e17 (39.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.97\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eM2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15 (46.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e8 (22.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e8 (32.00)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15 (34.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.81\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLesion volume (mL)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e71.4\u0026thinsp;\u0026plusmn;\u0026thinsp;63.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e26.0\u0026thinsp;\u0026plusmn;\u0026thinsp;33.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e20.21\u0026thinsp;\u0026plusmn;\u0026thinsp;22.49\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e63.1\u0026thinsp;\u0026plusmn;\u0026thinsp;61.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eOnset-to-ER (min)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e135 (79\u0026ndash;385)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e60 (25\u0026ndash;113)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e56 (27\u0026ndash;95)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e120 (60\u0026ndash;335)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDoor-to-puncture (min)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e119 (97\u0026ndash;143)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e106 (93\u0026ndash;122)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e134 (100\u0026ndash;195)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.19\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003ctfoot\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"7\"\u003eValues are presented as n (%), mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation, or median (interquartile range).\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"7\"\u003eEVT, endovascular therapy; INR, international normalized ratio; LDL, low-density lipoprotein; NIHSS, National Institute of Health Stroke Scale\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tfoot\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group had more atrial fibrillation, more distant metastasis, lower mean hemoglobin level, lower mean platelet count, prolonged prothrombin time, and higher mean C-reactive protein levels than the low \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group. The lesion volume was significantly larger and the onset-to-emergency room time was longer than that in the low \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group. Age, sex, baseline NIHSS, other comorbid disease, laboratory results, and occluded vessel site did not differ significantly between the groups.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eClinical outcomes\u003c/strong\u003e\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe clinical outcomes of each group are presented in Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e. Among the 36 patients treated with EVT, 20 (55.6%) had successful recanalization. The low \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group showed a higher successful recanalization rate than the high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group (73.68% vs. 35.29%, p\u0026thinsp;=\u0026thinsp;0.02) The incidence of hemorrhagic transformation was not significantly different. The EVT group showed a lower mean NIHSS score at discharge than the non-EVT group (median, 5.5 [interquartile range (IQR), 1.75\u0026ndash;14] vs. 16 [IQR, 7\u0026ndash;42], p\u0026thinsp;\u0026lt;\u0026thinsp;0.01), and the high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group showed a higher mean NIHSS score at discharge than the low \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group (median, 15.7 [IQR, 6.5\u0026ndash;40] vs. 4 [IQR, 1\u0026ndash;13], p\u0026thinsp;\u0026lt;\u0026thinsp;0.001).\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab2\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eClinical outcomes by EVT and \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer groups\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eNon-EVT\u003c/p\u003e\n\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;32)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eEVT\u003c/p\u003e\n\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;36)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP value\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level\u0026thinsp;\u0026lt;\u0026thinsp;4\u003c/p\u003e\n\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;25)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level\u0026thinsp;\u0026gt;\u0026thinsp;4\u003c/p\u003e\n\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;43)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP-value\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSuccessful recanalization (mTICI 2b\u0026ndash;3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e20 (55.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14 (73.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (35.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.02\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHemorrhagic transformations\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5 (15.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e6 (16.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.91\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4 (16.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7 (16.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.98\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNIHSS at discharge\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e16 (7\u0026ndash;42)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e5.5 (1.5\u0026ndash;14)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4 (1\u0026ndash; 13)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (15.7\u0026ndash;42)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMedian mRS score at 3 months\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (4.75\u0026ndash;6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e3.5 (1\u0026ndash;6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1 (1\u0026ndash;3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (5\u0026ndash;6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFavorable outcomes (mRS score of 0\u0026ndash;2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5 (15.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e13 (36.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.06\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15 (60.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3 (7.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMortality at 3 months\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e22 (68.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e12 (33.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3 (12.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e31 (72.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003ctfoot\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"7\"\u003eValues are number (%) or median (interquartile range).\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tfoot\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe median 3-month mRS score was significantly better in the EVT group than in the non-EVT group (median, 3.5 [IQR, 1\u0026ndash;6] vs. 6 [IQR, 4.75\u0026ndash;6], p\u0026thinsp;=\u0026thinsp;0.01) and significantly better in the low \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group than in the high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group (median, 1 [IQR, 1\u0026ndash;3] vs. 6 [IQR, 5\u0026ndash;6], p\u0026thinsp;\u0026lt;\u0026thinsp;0.01). The EVT group had more favorable outcomes, but the difference was not statistically significant. The low \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group had significantly more favorable outcomes than the high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group. The 3-month mortality rate was significantly higher in the non-EVT group than the EVT group and the high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group than the low \u003cspan class=\"SmallCaps\"\u003ed-\u003c/span\u003edimer group (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) (68.75% vs. 33.33%, 58.85% vs. 10.53%, respectively).\u003c/p\u003e\n\u003cp\u003eEVT and non-EVT groups showed poor 3-month mRS scores with high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels. Patients with low \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels and EVT showed the best outcomes, while those with high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels and non-EVT showed the worst outcomes. (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e)\u003c/p\u003e\n\u003cp\u003eThe cause of death was stroke-related in six patients (17.6%) and other medical problem\u0026ndash;related deaths in 28 patients (82.4%). A total of 10 (27.8%) patients showed early dramatic neurologic improvement in the EVT group. Among them, 10 underwent EVT and reported early dramatic improvement, 3 (30%) died, and the other 7 (70%) were alive at 3 months. The seven survivors included six from the low \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group and one from the high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eReceiver operating characteristic curve analysis\u003c/strong\u003e\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eFigure \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e shows the ROC of favorable outcomes and mortality by initial \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level. The areas under the curve were 0.896 and 0.869, respectively. The initial \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level was significantly related to a 3-month favorable outcome and mortality.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eLogistic regression analysis\u003c/strong\u003e\u003c/em\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\n\u003cp\u003eUnivariate and multivariate logistic regression analyses are presented in Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e. The risk factors for 3-month mortality were EVT (OR, 0.297; p\u0026thinsp;=\u0026thinsp;0.027) and an initially high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level (OR, 16.230; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). The negative correlation factors of clinically favorable outcomes were lesion volume (OR, 0.936; p\u0026thinsp;=\u0026thinsp;0.009) and high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels (OR, 0.098; p\u0026thinsp;=\u0026thinsp;0.005).\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab3\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eRegression analysis of mortality and favorable outcomes\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth colspan=\"2\" rowspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n\u003cth colspan=\"4\" align=\"left\"\u003e\n\u003cp\u003eMortality\u003c/p\u003e\n\u003c/th\u003e\n\u003cth colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n\u003cth colspan=\"4\" align=\"left\"\u003e\n\u003cp\u003eFavorable outcome\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003cth colspan=\"3\" align=\"left\"\u003e\n\u003cp\u003eUnivariate analysis\u003c/p\u003e\n\u003c/th\u003e\n\u003cth colspan=\"3\" align=\"left\"\u003e\n\u003cp\u003eMultivariate analysis\u003c/p\u003e\n\u003c/th\u003e\n\u003cth colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eUnivariate analysis\u003c/p\u003e\n\u003c/th\u003e\n\u003cth colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eMultivariate analysis\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eOR (95% CI)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eP value\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eOR (95% CI)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eP value\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eOR (95% CI)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eP value\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eOR (95% CI)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eP value\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eAge\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.96 (0.91\u0026ndash;1.01)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.12\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.03 (0.97\u0026ndash;1.09)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.37\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eMale sex\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.61 (0.62\u0026ndash;4.19)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.33\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.63 (0.21\u0026ndash;1.86)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.40\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eBaseline NIHSS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.05 (0.97\u0026ndash;1.13)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.94 (0.86\u0026ndash;1.02)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eHypertension\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.88 (0.33\u0026ndash;2.36)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.80\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.58 (0.18\u0026ndash;1.87)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.36\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eDiabetes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.29 (0.32\u0026ndash;5.30)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.72\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.47 (0.33\u0026ndash;6.60)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.62\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eHyperlipidemia\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.43 (0.12\u0026ndash;1.61)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.21\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.36 (0.64\u0026ndash;8.71)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.20\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eAtrial fibrillation\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.51 (0.14\u0026ndash;1.95)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.33\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.05 (0.25\u0026ndash;4.49)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.95\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eSmoking\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.88 (0.32\u0026ndash;2.40)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.80\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.68 (0.21\u0026ndash;2.23)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.53\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eAlcohol\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.62 (0.16\u0026ndash;2.44)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.50\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.27 (0.03\u0026ndash;2.28)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.23\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eLung cancer\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.79 (0.30\u0026ndash;2.05)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.63\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.00 (0.97\u0026ndash;9.30)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.06\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eDistant metastasis\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.05 (0.78\u0026ndash;5.39)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.15 (0.39\u0026ndash;3.41)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.80\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eHemoglobin\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.76 (0.60\u0026ndash;0.97)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.03\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.78 (0.60\u0026ndash;1.01)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.06\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.12 (0.88\u0026ndash;1.43)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.38\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003ePlatelet count\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.99 (0.99\u0026ndash;1.00)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.03\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.00 (0.99\u0026ndash;1.00)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.20\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.01 (1.00\u0026ndash;1.02)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.01 (1.00\u0026ndash;1.02)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eLDL-cholesterol\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.00 (0.98\u0026ndash;1.01)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.68\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.01 (0.99\u0026ndash;1.02)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.51\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eC-reactive protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.08 (1.00\u0026ndash;1.17)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.07\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.93 (0.83\u0026ndash;1.03)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eOccluded segment\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eMCA M1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.45 (0.55\u0026ndash;3.84)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.46\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.49 (0.15\u0026ndash;1.58)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.23\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eMCA M2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.67 (0.25\u0026ndash;1.85)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.44\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.87 (0.62\u0026ndash;5.66)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.27\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eDistal ICA\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.00 (0.34\u0026ndash;2.94)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e1.00\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.10 (0.33\u0026ndash;3.67)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.88\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eLesion volume, mL\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.01 (1.00\u0026ndash;1.02)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.93 (0.88\u0026ndash; 0.98)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.94 (0.89\u0026ndash; 0.98)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eOnset-to-ER\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.00 (1.00\u0026ndash;1.01)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.03\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.00 (1.00\u0026ndash;1.01)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.05\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.10 (0.99\u0026ndash;1.00)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.11\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eMechanical thrombectomy\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.23 (0.08\u0026ndash;0.63)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.30 (0.10\u0026ndash;0.87)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.030\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.05 (0.95\u0026ndash;9.85)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.06\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.02 (0.19\u0026ndash;5.37)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.98\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer\u0026thinsp;\u0026gt;\u0026thinsp;4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e18.94 (4.78\u0026ndash;75.16)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" align=\"left\"\u003e\n\u003cp\u003e16.23 (4.02\u0026ndash;65.58)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.05 (0.01\u0026ndash;0.21)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.10 (0.02\u0026ndash;0.50)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.05\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eA significant proportion of acute stroke patients with LVO had active cancer at presentation, a low successful recanalization rate, a higher probability of disability at 3 months, and higher mortality. \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level was an independent prognostic factor for favorable outcomes and mortality among acute stroke patients with active cancer irrespective of EVT. In addition, the initial \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level tended to be inversely correlated with recanalization grade, although the trend was not statistically significant. Therefore, the treatment effect of EVT was affected by the baseline \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level, suggesting that \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer can be a useful determinant of EVT in acute stroke patients with active cancer.\u003c/p\u003e\n\u003cp\u003ePrevious studies showed a significantly worse prognosis in patients with active cancer than in those without cancer when treated with EVT.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e These results suggest that conventional criteria for the decision of EVT were inappropriate for acute stroke patients with active cancer, suggesting the unmet need for new prognostic factors.\u003c/p\u003e\n\u003cp\u003eThe etiology of stroke due to cancer-related coagulopathy is thought to differ from that of conventional stroke mechanisms. There have been emerging ideas of cancer-related stroke mechanisms, including intravascular coagulopathy, paradoxical embolisms with venous thromboembolism, and nonbacterial thrombotic endocarditis.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e Regarding these distinguishing etiologies of cancer-associated stroke, special consideration was made of unique stroke patterns involving multiple scattered lesions in multiple vascular territories that were associated with elevated \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer, a fibrin degradation product of a blood clot, is known to reflect coagulation mechanisms and hypercoagulability by direct measurement of activated coagulation and fibrinolysis.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e Several previous studies suggested the prognostic and diagnostic value of elevated \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels as a risk factor for stroke in patients with cancer or cardiovascular diseases.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e Cancer patients with high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels tend to show poor outcomes and a high mortality rate.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e Elevated \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels show the distinctive etiology of stroke but also reflect the general medical condition of patients with underlying cancer.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e Therefore, we hypothesized that the baseline \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level in acute stroke patients with active cancer can be used to predict the overall outcome. Although the \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level is used as a unique thrombosis biomarker, a specific level that predicts ischemic stroke is unknown. After the adjustment for EVT, our study showed that patients with elevated \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels above 4 \u0026micro;g/mL had about a 16-fold higher risk of death and a 90% lower chance of a favorable outcome at 90 days. We assumed that the \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level might help guide whether to proceed with EVT and predict clinical outcomes in LVO cancer stroke patients.\u003c/p\u003e\n\u003cp\u003eHowever, considering the cause of mortality among our research results, the general medical condition is more important for prognosis than the stroke itself. In determining the EVT of cancer patients, in addition to the pre-existing criteria, general medical conditions such as \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer should be considered together. Approximately one-third of EVT cancer patients showed dramatic rapid neurological improvement, and the majority of had low initial \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels and mortality was numerically higher in the high \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer group (two-thirds of patients) despite the achievement of the early dramatic neurological improvement. Therefore, we should assess the initial \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level when choosing EVT for a cancer patient, and if the \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer level is low, EVT can be considered appropriate.\u003c/p\u003e\n\u003cp\u003eBaseline \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels were associated with recanalization grade. The unique pathophysiology of intravascular coagulopathy, which often occurs in cancer patients, increases \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e Tissue factors, inflammatory cytokines, or cancer procoagulants from cancer cells affect factor X activation in the coagulation cascade.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e This mechanism results in the formation of a solid fibrin clot within the vessel without any embolic thrombus. A previous study revealed that thrombi from EVT in cancer patients showed a significantly higher fraction of platelets and fibrin-rich components than those in non-cancer stroke patients.\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. Further studies are needed to reveal the specific mechanism in cancer stroke patients.\u003c/p\u003e\n\u003cp\u003eThis study had several limitations. First, this study was conducted in a single center and included a relatively small sample size. Second, different cancer types and stages may have different effects on stroke. Third, the etiologies of stroke in patients with cancer may be diverse. In particular, atrial fibrillation was significantly more frequently observed in the EVT group.\u003c/p\u003e\n\u003cp\u003eDespite these limitations, our study revealed a significant relationship between initial \u003cspan class=\"SmallCaps\"\u003ed\u003c/span\u003e-dimer levels and clinical outcomes in patients with cancer-associated stroke and LVO.\u003c/p\u003e"},{"header":"Conclusion","content":" \u003cp\u003eIn conclusion, active cancer patients with LVO stroke treated with EVT showed low recanalization and poor clinical outcomes correlated with \u003cspan type=\"SmallCaps\" class=\"SmallCaps\" name=\"Emphasis\"\u003ed\u003c/span\u003e-dimer levels. The initial \u003cspan type=\"SmallCaps\" class=\"SmallCaps\" name=\"Emphasis\"\u003ed\u003c/span\u003e-dimer level was an independent factor predicting favorable clinical outcomes and mortality in patients with active cancer patients with LVO stroke. Therefore, careful patient selection for EVT among cancer-associated stroke patients with LVO according to the initial \u003cspan type=\"SmallCaps\" class=\"SmallCaps\" name=\"Emphasis\"\u003ed\u003c/span\u003e-dimer level is warranted.\u003c/p\u003e "},{"header":"Acronyms","content":"\u003cp\u003eEVT\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; endovascular thrombectomy\u003c/p\u003e\n\u003cp\u003eLVO\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; large vessel occlusion\u003c/p\u003e\n\u003cp\u003emTICI\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; modified Treatment in Cerebral Infarction\u003c/p\u003e\n\u003cp\u003emRS\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;modified Rankin Scale\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eNIHSS\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; National Institutes of Health Stroke Scale\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e: All of the data supporting the conclusions of this article are included within the article. The authors declare that data will be made available upon request.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e: None\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e: The authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSources of funding\u003c/strong\u003e: This study was funded by national research project ID 2020M3E5D2A01084891 from ministry of Health and Welfare in Republic of Korea.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions: \u003c/strong\u003eK.H.P peformed statistical analysis and wrote draft of manuscript, W.K.S made critical revisions of manuscript, tables and figures, and the other authors collected and stratified patient data. All authors contributed to and approved the final manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003cp\u003e1\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Jovin, T. G.\u003cem\u003e et al.\u003c/em\u003e Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. \u003cem\u003eNew England Journal of Medicine\u003c/em\u003e \u003cstrong\u003e372\u003c/strong\u003e, 2296-2306, doi:10.1056/NEJMoa1503780 (2015).\u003c/p\u003e\n\u003cp\u003e2\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Rinaldo, L., Cloft, H. J., Rangel Castilla, L., Rabinstein, A. A. \u0026amp; Brinjikji, W. Utilization rates of tissue plasminogen activator and mechanical thrombectomy in patients with acute stroke and underlying malignancy. \u003cem\u003eJ Neurointerv Surg\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e, 768-771, doi:10.1136/neurintsurg-2018-014480 (2019).\u003c/p\u003e\n\u003cp\u003e3\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Navi, B. B. \u0026amp; Iadecola, C. Ischemic stroke in cancer patients: A review of an underappreciated pathology. \u003cem\u003eAnn Neurol\u003c/em\u003e \u003cstrong\u003e83\u003c/strong\u003e, 873-883, doi:10.1002/ana.25227 (2018).\u003c/p\u003e\n\u003cp\u003e4\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Lee, D.\u003cem\u003e et al.\u003c/em\u003e Intra-arterial thrombectomy for acute ischaemic stroke patients with active cancer. \u003cem\u003eJ Neurol\u003c/em\u003e \u003cstrong\u003e266\u003c/strong\u003e, 2286-2293, doi:10.1007/s00415-019-09416-8 (2019).\u003c/p\u003e\n\u003cp\u003e5\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Jung, S.\u003cem\u003e et al.\u003c/em\u003e Procedural and clinical outcomes of endovascular recanalization therapy in patients with cancer-related stroke. \u003cem\u003eInterv Neuroradiol\u003c/em\u003e \u003cstrong\u003e24\u003c/strong\u003e, 520-528, doi:10.1177/1591019918776207 (2018).\u003c/p\u003e\n\u003cp\u003e6\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Ryu, J. A., Bang, O. Y. \u0026amp; Lee, G. H. D-dimer levels and cerebral infarction in critically ill cancer patients. \u003cem\u003eBMC Cancer\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 591, doi:10.1186/s12885-017-3588-7 (2017).\u003c/p\u003e\n\u003cp\u003e7\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Haapaniemi, E. \u0026amp; Tatlisumak, T. Is D-dimer helpful in evaluating stroke patients? A systematic review. \u003cem\u003eActa Neurol Scand\u003c/em\u003e \u003cstrong\u003e119\u003c/strong\u003e, 141-150, doi:10.1111/j.1600-0404.2008.01081.x (2009).\u003c/p\u003e\n\u003cp\u003e8\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Zaidat, O. O.\u003cem\u003e et al.\u003c/em\u003e Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. \u003cem\u003eStroke\u003c/em\u003e \u003cstrong\u003e44\u003c/strong\u003e, 2650-2663, doi:10.1161/STROKEAHA.113.001972 (2013).\u003c/p\u003e\n\u003cp\u003e9\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Schwarzbach, C. J.\u003cem\u003e et al.\u003c/em\u003e Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. \u003cem\u003eStroke\u003c/em\u003e \u003cstrong\u003e43\u003c/strong\u003e, 3029-3034, doi:10.1161/STROKEAHA.112.658625 (2012).\u003c/p\u003e\n\u003cp\u003e10\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Bang, O. Y.\u003cem\u003e et al.\u003c/em\u003e Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. \u003cem\u003eJ Stroke\u003c/em\u003e \u003cstrong\u003e22\u003c/strong\u003e, 1-10, doi:10.5853/jos.2019.02278 (2020).\u003c/p\u003e\n\u003cp\u003e11\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Tripodi, A. D-dimer testing in laboratory practice. \u003cem\u003eClin Chem\u003c/em\u003e \u003cstrong\u003e57\u003c/strong\u003e, 1256-1262, doi:10.1373/clinchem.2011.166249 (2011).\u003c/p\u003e\n\u003cp\u003e12\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Hou, H.\u003cem\u003e et al.\u003c/em\u003e Association of Level and Increase in D-Dimer With All-Cause Death and Poor Functional Outcome After Ischemic Stroke or Transient Ischemic Attack. \u003cem\u003eJ Am Heart Assoc\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, e018600, doi:10.1161/jaha.120.018600 (2021).\u003c/p\u003e\n\u003cp\u003e13\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Park, H.\u003cem\u003e et al.\u003c/em\u003e Histological features of intracranial thrombi in stroke patients with cancer. \u003cem\u003eAnn Neurol\u003c/em\u003e \u003cstrong\u003e86\u003c/strong\u003e, 143-149, doi:10.1002/ana.25495 (2019).\u003c/p\u003e\n\u003cp\u003e14\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; Fu, C. H.\u003cem\u003e et al.\u003c/em\u003e Fibrin and Platelet-Rich Composition in Retrieved Thrombi Hallmarks Stroke With Active Cancer. \u003cem\u003eStroke\u003c/em\u003e \u003cstrong\u003e51\u003c/strong\u003e, 3723-3727, doi:10.1161/strokeaha.120.032069 (2020).\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"cancer-related stroke, D-dimer, endovascular thrombectomy, large vessel occlusion, recanalization","lastPublishedDoi":"10.21203/rs.3.rs-512754/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-512754/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e This study aimed to investigate clinical outcome predictors of acute stroke patients with large vessel occlusion and active cancer and validate the significance of d-dimer levels for endovascular thrombectomy decisions.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eWe analyzed a prospectively collected hospital-based stroke registry to determine clinical EVT outcomes of acute stroke patients within 24 hours with following criteria: age≥18 years, NIHSS≥6, and internal carotid artery or middle cerebral artery lesion. All patients were classified into EVT and non-EVT groups. Patients were divided into two groups by initial d-dimer level. We explored variables potentially associated with successful recanalization as well as 3-month functional outcomes and mortality rates. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eAmong 68 patients, 36 were treated with EVT, with successful recanalization in 55.6%. The low d-dimer group showed a higher rate of successful recanalization and favorable outcome than the high d-dimer group. The mortality rate was higher in the high d-dimer group. EVT and high d-dimer level were independent predictors of mortality, whereas lesion volume and low d-dimer level were independently associated with favorable outcomes.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusions: \u003c/strong\u003ed-dimer level is a prognostic factor in acute LVO stroke patients with active cancer, and its high value for EVT decisions provisionally supports its testing in this patient population.\u0026nbsp;\u003c/p\u003e","manuscriptTitle":"Title: Significance of D-dimer in acute ischemic stroke patients with large vessel occlusion accompanied by active cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2021-05-13 00:30:53","doi":"10.21203/rs.3.rs-512754/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"8b1bc9f2-4472-4ae4-9d09-c76fdec08fba","owner":[],"postedDate":"May 13th, 2021","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":4279648,"name":"Neurology"}],"tags":[],"updatedAt":"2021-07-26T15:14:13+00:00","versionOfRecord":[],"versionCreatedAt":"2021-05-13 00:30:53","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-512754","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-512754","identity":"rs-512754","version":["v1"]},"buildId":"ApUGefWb6u5IBVtyqm6d5","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}